Celgene Corp (CELG) 87.64 $CELG
Final Glance: Biotechnology companies
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Mon Jul 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Early Glance: Biotechnology companies
AP - Mon Jul 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.
Why Celgene Stock Was Down 3% Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:05PM CDT
Celgene turned in a quarter that beat analyst expectations on the top and bottom lines, with revenue up 17% year-over-year and adjusted EPS up 18% year-over-year, yet the market didn't appear too impressed (the stock sold off about 3% today). In...
Shares of CELG Up 16.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 24, 4:50PM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 16.58% as of today's recent price of $86.19.
Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...
Celgene Stock Earnings: Key Takeaways
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 4:03PM CDT
Celgene is one of biotechnology's brightest shining stars. The company markets a slate of therapies, including its mega blockbuster multiple myeloma drug Revlimid, its fast-growing cancer drug Abraxane, and its newly launched autoimmune drug,...
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Video: Celgene, Alexion Earnings Top, But Stocks Fall
at Investor's Business Daily - Thu Jul 24, 10:39AM CDT
Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) both modestly beat Q2 estimates and raised their guidance Thursday morning, but their shares were falling in the stock market today as Wall Street seemed to hope for more. Celgene's...
Jim Cramer's Stop Trading: Consider Buying Celgene on Friday
at The Street - Thu Jul 24, 10:10AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, reasoned that investors should buy the weakness in Celgene.
Stocks Up And Down At Open; Under Armour, Facebook Surge
at Investor's Business Daily - Thu Jul 24, 9:31AM CDT
Stocks opened in a narrowly mixed stance Thursday. The Dow Jones industrial average and the S&P 500 inched up a fraction each. The Nasdaq dipped 0.1% as Qualcomm (QCOM), Celgene (CELG) and Alexion Pharmaceuticals (ALXN) dived after delivering...
Celgene's Narrow Beat on Second-Quarter Earnings Fails to Impress Investors; Shares Fall
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 9:23AM CDT
Celgene Corporation reported second-quarter earnings before the bell today, posting an adjusted diluted EPS of $0.90 on a split-adjusted basis, narrowly beating the Street's expectations by $0.01. The company generated $1.873 billion in revenue...
Final Glance: Biotechnology companies
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Mon Jul 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Early Glance: Biotechnology companies
AP - Mon Jul 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.
Why Celgene Stock Was Down 3% Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:05PM CDT
Celgene turned in a quarter that beat analyst expectations on the top and bottom lines, with revenue up 17% year-over-year and adjusted EPS up 18% year-over-year, yet the market didn't appear too impressed (the stock sold off about 3% today). In...
Shares of CELG Up 16.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 24, 4:50PM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 16.58% as of today's recent price of $86.19.
Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...
Celgene Stock Earnings: Key Takeaways
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 4:03PM CDT
Celgene is one of biotechnology's brightest shining stars. The company markets a slate of therapies, including its mega blockbuster multiple myeloma drug Revlimid, its fast-growing cancer drug Abraxane, and its newly launched autoimmune drug,...
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Video: Celgene, Alexion Earnings Top, But Stocks Fall
at Investor's Business Daily - Thu Jul 24, 10:39AM CDT
Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) both modestly beat Q2 estimates and raised their guidance Thursday morning, but their shares were falling in the stock market today as Wall Street seemed to hope for more. Celgene's...
Jim Cramer's Stop Trading: Consider Buying Celgene on Friday
at The Street - Thu Jul 24, 10:10AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, reasoned that investors should buy the weakness in Celgene.
Stocks Up And Down At Open; Under Armour, Facebook Surge
at Investor's Business Daily - Thu Jul 24, 9:31AM CDT
Stocks opened in a narrowly mixed stance Thursday. The Dow Jones industrial average and the S&P 500 inched up a fraction each. The Nasdaq dipped 0.1% as Qualcomm (QCOM), Celgene (CELG) and Alexion Pharmaceuticals (ALXN) dived after delivering...
Celgene's Narrow Beat on Second-Quarter Earnings Fails to Impress Investors; Shares Fall
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 9:23AM CDT
Celgene Corporation reported second-quarter earnings before the bell today, posting an adjusted diluted EPS of $0.90 on a split-adjusted basis, narrowly beating the Street's expectations by $0.01. The company generated $1.873 billion in revenue...
